JP6997767B2 - Ｃｄ２００変異体及びその使用 - Google Patents

Ｃｄ２００変異体及びその使用 Download PDF

Info

Publication number
JP6997767B2
JP6997767B2 JP2019511816A JP2019511816A JP6997767B2 JP 6997767 B2 JP6997767 B2 JP 6997767B2 JP 2019511816 A JP2019511816 A JP 2019511816A JP 2019511816 A JP2019511816 A JP 2019511816A JP 6997767 B2 JP6997767 B2 JP 6997767B2
Authority
JP
Japan
Prior art keywords
protein
mutant
protein according
fusion protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518788A (ja
JP2019518788A5 (cg-RX-API-DMAC10.html
Inventor
ハクスリー フィリップ
シェリダン ジョセフ
ヒール ジョナサン
Original Assignee
デュセンティス バイオセラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュセンティス バイオセラピューティクス リミテッド filed Critical デュセンティス バイオセラピューティクス リミテッド
Publication of JP2019518788A publication Critical patent/JP2019518788A/ja
Publication of JP2019518788A5 publication Critical patent/JP2019518788A5/ja
Application granted granted Critical
Publication of JP6997767B2 publication Critical patent/JP6997767B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019511816A 2016-05-10 2017-05-10 Ｃｄ２００変異体及びその使用 Active JP6997767B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608197.8 2016-05-10
GBGB1608197.8A GB201608197D0 (en) 2016-05-10 2016-05-10 Novel proteins
PCT/GB2017/051303 WO2017194941A1 (en) 2016-05-10 2017-05-10 Cd200 mutant and its uses

Publications (3)

Publication Number Publication Date
JP2019518788A JP2019518788A (ja) 2019-07-04
JP2019518788A5 JP2019518788A5 (cg-RX-API-DMAC10.html) 2020-06-25
JP6997767B2 true JP6997767B2 (ja) 2022-03-04

Family

ID=56297468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511816A Active JP6997767B2 (ja) 2016-05-10 2017-05-10 Ｃｄ２００変異体及びその使用

Country Status (14)

Country Link
US (1) US11203628B2 (cg-RX-API-DMAC10.html)
EP (1) EP3455247A1 (cg-RX-API-DMAC10.html)
JP (1) JP6997767B2 (cg-RX-API-DMAC10.html)
KR (2) KR102498901B1 (cg-RX-API-DMAC10.html)
CN (1) CN109219614B (cg-RX-API-DMAC10.html)
AU (1) AU2017264825B2 (cg-RX-API-DMAC10.html)
CA (1) CA3023601A1 (cg-RX-API-DMAC10.html)
EA (1) EA201892554A1 (cg-RX-API-DMAC10.html)
GB (1) GB201608197D0 (cg-RX-API-DMAC10.html)
IL (1) IL262846B2 (cg-RX-API-DMAC10.html)
MX (1) MX386295B (cg-RX-API-DMAC10.html)
SG (1) SG11201809677XA (cg-RX-API-DMAC10.html)
WO (1) WO2017194941A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807079B (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
KR102186780B1 (ko) 2019-02-18 2020-12-04 박주현 비행부와 탑승부를 분리하여 축으로 결합한 유인드론
CN110859951A (zh) * 2019-09-23 2020-03-06 中国药科大学 Cd200蛋白和cd200融合蛋白在制备治疗银屑病药物中的应用
GB202115803D0 (en) * 2021-11-03 2021-12-15 Ducentis Biotherapeutics Ltd Novel proteins
EP4519297A1 (en) * 2022-05-06 2025-03-12 Ducentis Biotherapeutics Limited Novel cd200 fusion proteins
CN119522234A (zh) * 2022-05-06 2025-02-25 杜森蒂斯生物治疗有限公司 新型cd200融合蛋白
GB2626300A (en) * 2022-12-08 2024-07-24 Ducentis Biotherapeutics Ltd Mutated CD200 proteins and methods of use therof
GB202303291D0 (en) 2023-03-07 2023-04-19 Secr Defence Medicament and medicament combination for use in the treatment of infectious disease
GB202306711D0 (en) * 2023-05-05 2023-06-21 Ducentis Biotherapeutics Ltd Novel proteins
WO2025106841A1 (en) * 2023-11-15 2025-05-22 The University Of Chicago Methods and compositions for inducing antigen specific tolerance

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066689A2 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2002541210A (ja) 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ｏｘ２タンパク質および関連試薬の新規な使用
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
JP2010515751A (ja) 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ２００およびそのレセプターｃｄ２００ｒは破骨細胞の分化を介して骨質量を調節する

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
KR20140053410A (ko) * 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CN102448982B (zh) * 2009-03-31 2018-04-20 华盛顿大学 用于调节靶细胞上补体调节蛋白的活性的组合物和方法
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001522867A (ja) 1997-11-07 2001-11-20 レジナルド・エム・ゴルツィンスキー 免疫調節のための方法および組成物
JP2002541210A (ja) 1999-04-13 2002-12-03 シェーリング コーポレイション 哺乳動物ｏｘ２タンパク質および関連試薬の新規な使用
WO2001066689A2 (en) 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2004513660A (ja) 2000-11-22 2004-05-13 トリリウム　セラピューティクス　インコーポレーティッド 切断型ｃｄ２００
JP2010515751A (ja) 2007-01-11 2010-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ２００およびそのレセプターｃｄ２００ｒは破骨細胞の分化を介して骨質量を調節する

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Structure (2013) Vol.21, pp.820-832
The Journal of Immunology (2003) Vol.171, pp.3034-3046
The Journal of Immunology (2005) Vol.175, pp.2469-2474

Also Published As

Publication number Publication date
KR102689460B1 (ko) 2024-07-26
KR20230025937A (ko) 2023-02-23
BR112018073280A2 (pt) 2019-03-19
IL262846B (en) 2022-10-01
NZ747665A (en) 2025-10-31
AU2017264825B2 (en) 2021-04-08
ZA201807079B (en) 2019-07-31
CN109219614A (zh) 2019-01-15
SG11201809677XA (en) 2018-11-29
MX386295B (es) 2025-03-18
US20190367580A1 (en) 2019-12-05
EA201892554A1 (ru) 2019-04-30
EP3455247A1 (en) 2019-03-20
IL262846B2 (en) 2023-02-01
KR20190003761A (ko) 2019-01-09
KR102498901B1 (ko) 2023-02-10
JP2019518788A (ja) 2019-07-04
CN109219614B (zh) 2022-05-24
US11203628B2 (en) 2021-12-21
GB201608197D0 (en) 2016-06-22
IL262846A (en) 2018-12-31
AU2017264825A1 (en) 2018-11-15
WO2017194941A1 (en) 2017-11-16
CA3023601A1 (en) 2017-11-16
MX2018013778A (es) 2019-08-01

Similar Documents

Publication Publication Date Title
KR102689460B1 (ko) Cd200 돌연변이체 및 그의 용도
KR20180012856A (ko) 면역반응의 조절을 위한 방법 및 폴리펩타이드
CN120187445A (zh) 用于治疗炎症和自身免疫性疾病的方法和组合物
JP7830450B2 (ja) 修飾されたｉｌ－２分子及びその用途
JP2025515191A (ja) 新規ｃｄ２００融合タンパク質
US20250026805A1 (en) Novel proteins
Wang et al. Site-specific dimerization of interleukin-11 alleviates bleomycin-induced pulmonary fibrosis in mice
JP2024500250A (ja) Ｃｏｖｉｄ－１９の治療のためのｄｓｇ２組成物及び方法
WO2018223118A1 (en) Use of tetranectin and peptide agonists to treat inflammatory diseases
WO2024125445A1 (zh) 一种靶向TNF-α与IL-17A的双特异性融合蛋白及其用途
CA2688543C (en) Vegf-d mutants and their use
EA042608B1 (ru) Мутант cd200 и его применения
BR112018073280B1 (pt) Proteína cd200 mutada, proteína de fusão compreendendo a mesma, composição farmacêutica e uso das referidas proteínas ou composição para o tratamento de doença autoimune
US20260116951A1 (en) Novel cd200 fusion proteins
JP2026516066A (ja) Ｃｄ２００融合タンパク質
CN110156897A (zh) 一种包含TRAIL和IgG结合结构域的融合蛋白及其用途
JP2021080171A (ja) 改変タンパク質、医薬品、炎症性疾患の予防又は治療剤及び改変タンパク質の製造方法
HK1255673A1 (en) Methods and polypeptides for modulation of immunoresponse

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211217

R150 Certificate of patent or registration of utility model

Ref document number: 6997767

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250